BIOSTAR PHARM-B Keeps Share Capital Unchanged at 364.59 Million H Shares in April 2026, Confirms Sufficient Public Float

Bulletin Express05-06

Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) filed its monthly return for the period ended 30 April 2026, showing no movement in either registered or issued capital.

The company’s registered share capital remained at 364,588,000 ordinary H shares with a par value of RMB 1 each, equivalent to 364.59 million shares. No increase or decrease was recorded during the month.

Issued share data mirrored the registered figures: 364,588,000 shares were outstanding at both the beginning and end of April, and the company continued to hold zero treasury shares.

Biostar reaffirmed that it satisfies the Main Board’s minimum public-float threshold of 25 percent for its H-share class.

No share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised in the reporting month.

The company highlighted that it had completed full circulation on 30 March 2026 by converting 147.87 million previously unlisted shares into H shares; this conversion did not affect April’s totals.

The monthly return was submitted by Company Secretary Chan Yik Pun on 6 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139237801?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139237801","market":"hk","top_or_hot":-1,"title":"BIOSTAR PHARM-B Keeps Share Capital Unchanged at 364.59 Million H Shares in April 2026, Confirms Sufficient Public Float","media":"Bulletin Express","content":"<p>Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) filed its monthly return for the period ended 30 April 2026, showing no movement in either registered or issued capital.</p>\n<p>The company’s registered share capital remained at 364,588,000 ordinary H shares with a par value of RMB 1 each, equivalent to 364.59 million shares. No increase or decrease was recorded during the month.</p>\n<p>Issued share data mirrored the registered figures: 364,588,000 shares were outstanding at both the beginning and end of April, and the company continued to hold zero treasury shares.</p>\n<p>Biostar reaffirmed that it satisfies the Main Board’s minimum public-float threshold of 25 percent for its H-share class.</p>\n<p>No share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised in the reporting month.</p>\n<p>The company highlighted that it had completed full circulation on 30 March 2026 by converting 147.87 million previously unlisted shares into H shares; this conversion did not affect April’s totals.</p>\n<p>The monthly return was submitted by Company Secretary Chan Yik Pun on 6 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOSTAR PHARM-B Keeps Share Capital Unchanged at 364.59 Million H Shares in April 2026, Confirms Sufficient Public Float</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOSTAR PHARM-B Keeps Share Capital Unchanged at 364.59 Million H Shares in April 2026, Confirms Sufficient Public Float\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) filed its monthly return for the period ended 30 April 2026, showing no movement in either registered or issued capital.</p>\n<p>The company’s registered share capital remained at 364,588,000 ordinary H shares with a par value of RMB 1 each, equivalent to 364.59 million shares. No increase or decrease was recorded during the month.</p>\n<p>Issued share data mirrored the registered figures: 364,588,000 shares were outstanding at both the beginning and end of April, and the company continued to hold zero treasury shares.</p>\n<p>Biostar reaffirmed that it satisfies the Main Board’s minimum public-float threshold of 25 percent for its H-share class.</p>\n<p>No share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised in the reporting month.</p>\n<p>The company highlighted that it had completed full circulation on 30 March 2026 by converting 147.87 million previously unlisted shares into H shares; this conversion did not affect April’s totals.</p>\n<p>The monthly return was submitted by Company Secretary Chan Yik Pun on 6 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"华昊中天医药-B","start_time":0,"source_url":"","article_id":"1139237801","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139237801","pubTimestamp":1778077382,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) filed its monthly return for the period ended 30 April 2026, showing no movement in either registered or issued capital. The company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02563":"华昊中天医药-B"},"translate_title":"映泰医药-B于2026年4月维持股本3.6459亿股H股不变，确认公众持股量充足","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":1},"content_text":"Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) filed its monthly return for the period ended 30 April 2026, showing no movement in either registered or issued capital.\nThe company’s registered share capital remained at 364,588,000 ordinary H shares with a par value of RMB 1 each, equivalent to 364.59 million shares. No increase or decrease was recorded during the month.\nIssued share data mirrored the registered figures: 364,588,000 shares were outstanding at both the beginning and end of April, and the company continued to hold zero treasury shares.\nBiostar reaffirmed that it satisfies the Main Board’s minimum public-float threshold of 25 percent for its H-share class.\nNo share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised in the reporting month.\nThe company highlighted that it had completed full circulation on 30 March 2026 by converting 147.87 million previously unlisted shares into H shares; this conversion did not affect April’s totals.\nThe monthly return was submitted by Company Secretary Chan Yik Pun on 6 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139237801","isCrawlerRequest":true}